(Q547551)

English

Nicholas Lydon

British biochemist

Statements

Nicholas Lydon.jpg
2,400 × 3,613; 491 KB
0 references
0 references
0 references
0 references
0 references
For the development of molecularly-targeted treatments for chronic myeloid leukemia, converting a fatal cancer into a manageable chronic condition. (English)
For development of Abl kinase inhibitors for use in the treatment of chronic myelogenous leukemia. (English)
"for their development of imatinib and dasatinib, revolutionary, targeted treatments for chronic myeloid leukemia." (English)

Identifiers

 
edit
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit